This website uses cookies to ensure you get the best experience on our website. Privacy Policy
Accept
all report title image

NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

Neurological Biomarkers Market, By Biomarker Type (Artificial Tears, Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, Genomics Biomarkers), By Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, Others), By End User (Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Feb 2025
  • Code : CMI4586
  • Pages :174
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Neurological Biomarkers Market Size and Trends

Global neurological biomarkers market is estimated to be valued at USD 9.64 Bn in 2025 and is expected to reach USD 23.12 Bn by 2032, exhibiting a compound annual growth rate (CAGR) 13.3% from 2025 to 2032.

Neurological Biomarkers Market Key Factors

To learn more about this report, Request sample copy

The market is expected to witness positive growth over the forecast period due to  factors such as rising incidences of neurological disorders, increasing research & development activities related to neurological diseases, rising adoption of imaging biomarkers and growing demand for minimally invasive testing. Furthermore, ongoing research to develop novel molecular biomarkers for neuropsychiatric conditions can provide opportunities for the market players. With recent technological advancements, neurological biomarkers have emerged as potential diagnostic tools and their clinical utility is under active research globally.

Rising Incidence of Neurological Disorders

Global neurological biomarkers market growth is primarily driven by rising prevalence of neurological disorders worldwide. According to various studies, neurological disorders are becoming one of the leading causes of disability and mortality. Neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and others pose a major health burden. It is estimated that over 1 billion people suffer from some form of neurological disorder. Alzheimer's disease and epilepsy affect over 35 million and 65 million people respectively. Traumatic brain injury cases are increasing due to increasing road accidents globally. All these neurological conditions requires continuous monitoring of disease progression and treatment response through reliable biomarkers, which can aid clinical decision making. Growing incidence of neurological disorders due to growing aging population and changing lifestyle factors can boost demand for neurological biomarkers in the near future. For instance, according to the data published by WHO on March 14, 2025, a new study from the Lancet Neurology reveals that over 3 billion people globally lived with neurological conditions in 2021, making these the leading cause of illness and disability worldwide. Disability, illness, and premature death attributed to neurological conditions have increased by 18% since 1990. Most neurological deaths and health loss occur in low- and middle-income countries, where access to treatment is significantly limited compared to high-income countries.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.